Last reviewed · How we verify

NCT03110393

Ambu®AuraGain™ Versus I-gel® in Obese Patients

Completed NA Last updated 8 January 2018
What this trial tests

NA trial testing Ambu AuraGain in Obese in 44 participants. Completed in 6 September 2017.

Timeline
20 April 2017
Primary endpoint
6 September 2017
6 September 2017

Quick facts

Lead sponsorSchulthess Klinik
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment44
Start date20 April 2017
Primary completion6 September 2017
Estimated completion6 September 2017
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

Schulthess Klinik

Who can join

Adults 18 to 70, any sex, with Obese. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is the randomized comparison of two laryngeal mask (Intersurgical i-gel® and Ambu®AuraGain™) in obese patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ambu AuraGain

Trials testing the same drug.

Other recruiting trials for Obese

Currently open trials in the same condition.

Other Schulthess Klinik trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03110393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing